Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2017-10-15 Director's Dealing
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Strong demand for MVP Shares 2 pages 250.4KB
Director's Dealing Classification · 95% confidence The document is an ASX announcement dated 16 October 2017 regarding the sale of shares by the Chairman of Medical Developments International Ltd to financial institutions. It discusses the liquidity event and demand for shares but does not contain financial statements, detailed financial results, or regulatory certifications. The document is relatively short (3337 characters) and focuses on a transaction involving shares by a company director. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives. There is no indication that this is a full financial report, earnings release, or other types of filings. Therefore, the appropriate classification is Director's Dealing (DIRS).
2017-10-15 English
Appendix 3B 12 pages 689.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares, including the number of shares issued, issue price, purpose of the issue, and compliance with ASX listing rules. It includes sections on placement capacity calculations under ASX rules 7.1 and 7.1A, and a quotation agreement for the new securities. The document is a formal announcement related to the issuance and quotation of additional securities on the Australian Securities Exchange (ASX). This type of document is specifically used to announce new share issues and capital changes, not a full financial report or earnings release. Therefore, it fits the category of 'Share Issue/Capital Change' (SHA). The document length is substantial and contains detailed issuance data, confirming it is not merely a brief announcement or a report publication notice.
2017-10-05 English
Change of Director's Interest Notice 12 pages 632.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including the number of shares held before and after changes, nature of interests, and dates of changes. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains multiple such notices for different directors, confirming it is not a brief announcement but a detailed report of insider transactions.
2017-10-05 English
Penthrox recommended for use in all UK ambulances 2 pages 268.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 26 September 2017, informing that Penthrox has been recommended for use in all UK ambulances by the Joint Royal Colleges Ambulance Liaison Committee (JRCALC). It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or operational report. The document is a corporate announcement about a product recommendation and market potential, typical of a general regulatory announcement. The document length is 4079 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2017-09-25 English
Annual Report to shareholders 72 pages 7.7MB
Annual Report Classification · 100% confidence The document is titled 'Full-Year Report 2017' and covers the financial year ended 30 June 2017, with detailed financial results such as revenue growth, net profit, dividend declaration, and extensive discussion of business operations, regulatory approvals, sales growth, and future outlook. It includes comprehensive financial and operational data, management commentary, and strategic plans. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content aligns with an Annual Report (10-K equivalent) as it provides a full-year overview of company performance and outlook. There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the appropriate classification is Annual Report (10-K). FY 2017
2017-09-20 English
Notice of Annual General Meeting/Proxy Form 11 pages 786.8KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Fourteenth Annual General Meeting' and includes detailed information about the AGM such as date, location, agenda items including financial statements, remuneration report, election of directors, amendments to the constitution, and voting procedures. It is a notice informing shareholders about the upcoming AGM and the business to be conducted, rather than the actual reports or results themselves. The document length is about 15,000 characters, which is consistent with a detailed AGM notice. There is no actual financial data or report content included, only references to reports to be considered at the meeting. Therefore, this document fits the category of AGM Information (AGM-R).
2017-09-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.